Journal

Tirzepatide and Diabetes Prevention Over 176 Weeks

Use peer-reviewed trial data

The longest look we have

Most obesity trials run 68 to 72 weeks. This analysis followed participants for 176 weeks of treatment — about three and a half years — followed by a 17-week off-treatment period, in the subgroup who had prediabetes as well as obesity at enrolment.

Three years of tirzepatide produced substantial and sustained weight reduction and a markedly lower risk of progressing to type 2 diabetes compared with placebo.

Why this result carries more weight than a weight-loss figure

Progression to type 2 diabetes is a hard clinical outcome with consequences that compound over decades. A percentage on a scale is a surrogate; developing diabetes or not is the thing itself. Trials that measure hard outcomes over years are more informative than trials that measure surrogates over months, and there are far fewer of them.

The caveats that belong with it

It applies to a specific population — people with both obesity and prediabetes. It does not describe the general population or people with obesity alone.

Seventeen weeks off treatment is short. Given SURMOUNT-4's finding that withdrawal is followed by substantial regain, a short off-treatment window cannot establish that risk reduction persists. "Delayed progression while treated" and "prevented diabetes" are different claims, and only the first is supported.

Industry-funded and industry-analysed, as with the whole programme.

What it means practically

For someone with obesity and prediabetes, this is among the stronger pieces of evidence in the field, and it is a reasonable thing to discuss with a clinician. It does not tell you whether treatment can eventually stop, and the available evidence points toward continuation being necessary to hold the benefit.

Source

Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med, published 13 November 2024, updated 6 March 2025. DOI 10.1056/NEJMoa2410819. ClinicalTrials.gov NCT04184622.

Why prediabetes is the right population for this question

Prediabetes is a defined risk state with a measurable transition endpoint. That makes it one of the few settings where a weight-management drug can be tested against a hard clinical outcome rather than a surrogate, within a timeframe a trial can cover.

Of the 2,539 participants randomised in SURMOUNT-1, 1,032 had both obesity and prediabetes. Those participants continued for 176 weeks of treatment followed by a 17-week off-treatment period.

Delay against prevention

The distinction is not pedantic. "Prevented" implies the risk is removed. "Delayed while treated" implies it returns when treatment stops — and the 17-week off-treatment window is far too short to distinguish between them.

SURMOUNT-4 gives reason for caution: withdrawal was followed by 14% weight regain over a year. If progression risk tracks weight, then progression risk plausibly tracks regain.

The honest reading is that three years of treatment substantially reduced progression during treatment, and that what happens afterwards is not established.

What this means for someone with obesity and prediabetes

It is among the stronger pieces of evidence in this field, and a reasonable thing to raise with a clinician. It also implies an open-ended commitment rather than a course, which is a financial fact as much as a clinical one.

Over five years, that commitment is roughly $11,160 on a flat-rate compounded plan at $186 a month, about $8,940 on an approved oral held at a low dose, and around $26,940 on brand at a maintenance tier. For eligible Medicare enrollees the Bridge programme is $50 a month through 2027, with no confirmed successor.

What the analysis does not cover

People with obesity but without prediabetes. People with established type 2 diabetes. Any compounded preparation, microdose or oral formulation. And the durability question, which needs a longer off-treatment follow-up than this trial performed.

Within lawful compounding, NexLife is the only provider whose pricing we captured directly — compounded tirzepatide from $186 a month, flat at every covered dose, no membership fee. See its plans.

Questions readers actually ask